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Abstract Extracellular superoxide dismutase (EC-SOD) is
synthesized in mesenchymally derived cells and prevents the
oxygen radical-induced injury. We studied whether kidney
mesangial cells (MCs) produce EC-SOD and how its production
is associated with chemokine secretion. Under unstimulated
condition, MCs produced EC-SOD, and its production was
correlated positively with cyclic adenosine monophosphate
(cAMP), but negatively with interleukin (IL)-6 or IL-8 produc-
tion. By prednisolone or phorbol myristate acetate treatment,
EC-SOD levels were correlated negatively with levels of IL-6
and IL-8. The presence of adenylate cyclase inhibitor 2P,3P-
dideoxyadenosine lost the prednisolone effect. The stimulation of
EC-SOD production might be one of the important effects of
prednisolone via cAMP pathway in MCs. 1 2002 Federation
of European Biochemical Societies. Published by Elsevier Sci-
ence B.V. All rights reserved.
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1. Introduction
The oxygen radicals generated by activated neutrophils,
macrophages and glomerular cells have been implicated in
the progression of glomerulo-nephritis, and they are removed
by superoxide dismutase (SOD) [1,2]. Extracellular SOD (EC-
SOD) is the major SOD isozyme acting in the extracellular
space localized on the surface of the endothelium and vascular
smooth muscle cells [3,4]. Intracellularly it exists in much
smaller amounts than copper, zinc-SOD or manganese-SOD
[3]. EC-SOD, which is an anti-in£ammatory enzyme against
oxygen radical-related in£ammation in extracellular space, is
produced from mesenchymally derived cells such as ¢bro-
blasts, smooth muscle cells and glioma cells [3,5,6]. For the
regulation of EC-SOD production, the cyclic adenosine
monophosphate (cAMP) pathway is conceived to be impor-
tant in vivo and vitro [7].
EC-SOD is a secretory tetrameric copper- and zinc-contain-
ing glycoprotein with a subunit molecular weight of about 30
kDa and is mainly localized on the surface of endothelial cells
to express its activity e¡ectively in the vascular system [8]. It
was also con¢rmed by in vivo and in vitro studies that binding
of EC-SOD to heparan sulfate residues on the cell membrane
or matrix is an important feature in expressing the enzyme
activity and protecting from oxygen radicals generated by
activated leucocytes [4,9]. Moreover, EC-SOD plays a role
in prolonging the lifespan of nitric oxide [10] and decreases
the net production of powerfully oxidizing peroxynitrite [11].
In renal tissue, heparan sulfate proteoglycans are essential
components of the glomerular basement membrane and me-
sangial matrix as well as cell membrane carrying a strong
anionic charge, which is partly produced by the glomerular
mesangial cells (MCs) [12]. It is still unclear from in vivo or
vitro studies whether MCs, which are derived from mesen-
chyme cells, are able to produce EC-SOD.
MCs are in a pivotal position to organize the glomerular
function in the process of immune injury, because MCs have
been shown to produce oxygen radicals, cytokines and extra-
cellular matrix by immunological and pharmacological stim-
ulation [13^15]. MCs have a direct or indirect role in the
initiation and propagation of in£ammatory events, partly by
producing chemotactic cytokine interleukin (IL)-6- and IL-8-
recruiting neutrophils and macrophages. In in£ammation, the
activated neutrophils and macrophages are the major source
of oxygen radicals [16^18].
In vitro, MCs in culture show several interesting actions
under glucocorticoid or phorbol myristate acetate (PMA)
stimulation [19]. Glucocorticoid constitutes the ¢rst-line of
therapy in human nephrotic syndrome [20] and puromycin
aminonucleoside nephrosis [21] in rats in which oxygen radi-
cals are important factors in the pathogenesis [22]. In contrast,
PMA stimulation causes the hyperproduction of extracellular
matrix component through the modulation of MCs due to
protein kinase C (PKC) activation [19]. PKC activation is
associated with the hyperproduction of chemokines and oxy-
gen radical production under high glucose [23] or angiotensin
II stimulation [24] in vitro, thus mimicking the pathological
condition.
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This study was designed to examine ¢rst, whether MCs
produce EC-SOD and second, how the production is in£u-
enced by corticosteroid or PMA. We also examined the rela-
tionship between the production of EC-SOD and that of IL-6,
IL-8 or cAMP by MCs.
2. Materials and methods
2.1. MC culture
MCs were immediately isolated by a di¡erential sieving method
from the normal part of the human kidney cortex after surgical neph-
rectomy of 15 renal carcinoma cases as previously described [25]. The
MCs were grown in tissue culture £asks or 6-well tissue culture plates
in Dulbecco’s modi¢ed Eagle’s medium with 10% heat-inactivated
fetal calf serum and antibiotics. The MC identity was con¢rmed by
the appearance of characteristic hillock structures under the micro-
scope. By using a series of cell markers, intermediate ¢lament desmin,
myosin and vimentin, the purity of MCs was over the 98%. The MCs
used in this study were between passages 3 and 5.
2.2. MC stimulation with prednisolone and PMA
To clarify the change in EC-SOD production from stimulated MCs,
the EC-SOD content in culture media was analyzed for 3 days after
the addition of prednisolone or PMA. The added contents in the
culture media of MCs were 0.1, 0.5, 1 and 10 nM of PMA and 0.1,
0.5, 1, 5 and 10 WM of prednisolone.
2.3. Inhibition of adenylate cyclase activity by 3,5-deoxyadenosine
To study the participation of cAMP system in EC-SOD production,
MCs was analyzed using 2P,3P-dideoxyadenosine (DDA) as the ade-
nylate cyclase inhibitor [26]. The DDA contents in culture media were
1, 5, 10, 50 and 100 WM.
2.4. Enzyme-linked immunosorbent assay (ELISA) for cAMP
A competitive ELISA was used for the measurement of cAMP. The
cAMP ELISA system was the Titer Zyme Dual Range cAMP EIA,
purchased from PerSeptive Biosystem (Framingham, MA, USA). The
working range for measurement of cAMP was from 0.25 pmol/ml to
100 pmol/ml.
2.5. Measurement of EC-SOD, IL-6 and IL-8 levels
A two-step ELISA method was used for the measurement of EC-
SOD and IL-8. The EC-SOD ELISA system was our original system
as described previously [27]. IL-6 and IL-8 were measured using an
ELISA system purchased from Fuji-Rebio, Tokyo, Japan. The work-
ing ranges for the measurement of EC-SOD, IL-6 and IL-8 were from
50 pg/ml to 50 ng/ml, 15 pg/ml to 40 ng/ml and 20 pg/ml to30 ng/ml,
respectively. We con¢rmed that this ELISA system for EC-SOD
showed no cross-reactivity with other SOD isozymes.
3. Results and discussion
3.1. EC-SOD production from kidney glomerular cells
The kidney glomerulus is composed of three kinds of em-
bryologically di¡erent cells: endothelial cells, epithelial cells
and MCs. MCs are mesenchymally derived cells like smooth
muscle. MCs are involved in a number of important functions
including glomerular ¢ltration, antigen presentation, cytokine
production, phagocytosis, matrix synthesis and superoxide
production, as well as anatomical support for the glomerular
capillary loops [14].
In this study, the amount of EC-SOD production by MCs
was studied in the culture supernatant, which was changed
every 2 days. MC growth reached an optically con£uent state
in 10 days. The EC-SOD production was recognized in the
early stage, reached a plateau of 3.42Q 0.59 ng/ml/mg of pro-
tein in average about 20 days from the start of culture and
showed stable production thereafter. To con¢rm the EC-SOD
contents in the culture media re£ects the majority of EC-SOD
production by MCs, we compared the EC-SOD content in the
culture media with that in MCs cell fraction. Over 95% of EC-
SOD exists in the culture media, not stuck in the MCs surface.
In vivo, most part of EC-SOD is localized in the surface of
cells binding to heparan sulfate residues, however, in vitro, the
major part of EC-SOD is secreted in the medium, presumably
because cultured cells possess limited amount of heparan sul-
fate residues on the surface.
We also studied the EC-SOD production by kidney inter-
stitial cells : ¢broblasts and renal tubular epithelial cells. Pri-
mary cultured human kidney ¢broblasts and Green Monkey
kidney ¢broblasts: COS7 cells expressed EC-SOD, while hu-
man cultured renal tubular epithelial cells did not (data not
shown). Our results con¢rmed that MC in culture continu-
ously produce EC-SOD. It has been reported that smooth
muscle cells, glioma cells, skin ¢broblasts, osteoblastic cells
and lipid-laden macrophages are capable of producing EC-
SOD [3,28].
3.2. The relation of EC-SOD production with cAMP and
chemokines in MCs
To study the relation between the EC-SOD and chemokines
production, the culture media of MCs were analyzed under
the conventional unstimulated conditions in 20 days. As Fig. 1
shows, the EC-SOD levels showed a positive correlation with
cAMP and a negative correlation with IL-6 and IL-8 produc-
tion, indicating that EC-SOD production is closely related to
the in£ammation regulatory system through the cAMP sys-
tem.
3.3. Suppression of EC-SOD production due to PMA
stimulation
In vitro, PMA induces the stimulation of PKC that pro-
motes the production of matrix components [19,29], oxygen
radical generation [1,30] and chemokine production [31,32],
thus mimicking the state of glomerular injury. As Fig. 2A
shows, PMA stimulation to MCs results in a decrease in
Fig. 1. Production of EC-SOD, IL-6, IL-8 and cAMP of MCs in
individual cases. MCs production of cAMP, IL-6 and IL-8 for
EC-SOD production in individual cases under the unstimulated con-
ditions. Data were determined in triplicate. The dose value shows
IL-8 (R), IL-6 (b) and cAMP (a).
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EC-SOD with cAMP production and an increase in IL-6 and
IL-8 production in a dose-dependent manner.
In the process of glomerular injury, where local production
of in£ammatory cytokines such as IL-6 and IL-8 by MCs and
recruitment of in£ammatory cells are involved [16,17], oxygen
radicals are over-produced. Against these reactive oxygen rad-
icals, SOD acts as a protective protein. Our data suggest that
MCs suppress the production of EC-SOD when they are ac-
tivated by PMA, resembling the state of in£ammation. The
decrease of EC-SOD production by the PKC activation due
to the in£ammatory stimulation may play a pathophysiolog-
ical role in the progression of glomerular injury. In the long
term this situation may lead to the glomerular and vascular
malfunction. We reported in a clinical study in chronic hemo-
dialysis patients with diabetes, that those patients with genetic
substitution in the EC-SOD molecule are prone to vascular
injury and have a poor prognosis, suggesting that the pro-
longed defect of EC-SOD action a¡ects the prognosis [33].
3.4. E¡ect of prednisolone on EC-SOD, IL-6, IL-8 and cAMP
generation by MC
The regulatory mechanisms of EC-SOD production in MCs
on glucocorticoid stimulation were studied together with the
production of IL-6 and IL-8. As Fig. 2B shows, glucocorti-
coid treatment increased the EC-SOD and cAMP production
in a dose-dependent manner, and decreased the IL-6 and IL-8
production. These results indicate the suppression of chemo-
tactic cytokines by prednisolone occurred concomitantly with
the enhanced EC-SOD production through the cAMP regu-
lation.
The activation of gene transcription by glucocorticoids is
widely known to involve the binding of the hormone^receptor
complex to a consensus sequence within the cis transcriptional
control element of the gene (glucocorticoid responsive ele-
ment; GRE) [34]. A half-site for the GRE is located at
3189 bp (TGTCCT) of the transcription initiation site in
the human EC-SOD genome sequence [35]. Steroid-induced
gene regulation in the various tissues and vascular wall is
achieved through the interaction of speci¢c receptor proteins
Fig. 2. Production of EC-SOD, IL-6, IL-8 and cAMP of MCs by stimulated condition. A: Dose-dependent suppression of EC-SOD and
cAMP, induction of IL-6 and IL-8 by PMA stimulation of MCs (n=15). B: Dose-dependent induction of EC-SOD and cAMP, suppression of
IL-6 and IL-8 by prednisolone of MCs (n=15). Values are shown compared to the control, and were determined in triplicate. Statistical signi¢-
cance was calculated by ANOVA with the Bonferroni post test relative to the control value with *P6 0.05 and **P6 0.01.
Fig. 3. Under the presence of adenylate cyclase inhibitor (DDA),
EC-SOD, IL-6, IL-8 and cAMP production of MCs stimulating by
prednisolone. Data were determined in triplicate. The dose value
shows IL-8 (R), IL-6 (b) and cAMP (a).
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and promoters of the target genes. Prednisolone enhances the
production of cAMP in renal tubular cells under the stimu-
lated conditions and reduces the production of in£ammatory
cytokines [36]. cAMP also regulates IL-6 and IL-8 production
in IL-1-stimulated human MCs [37]. Our data demonstrated
that the promotion of EC-SOD production by prednisolone
treatment was associated with the elevation of cAMP content
and the decrease of IL-6 and IL-8. This study cannot clarify
whether the enhancement of EC-SOD production was a direct
or indirect role of cAMP and/or glucocorticoid.
Our results suggest that the anti-in£ammatory e¡ect of
prednisolone treatment is not only due to the suppression of
cytokines but also to the enhancement of EC-SOD produc-
tion. A novel hypothesis has recently been postulated based
on the results of a series of animal studies indicating that the
therapeutic e¡ect of steroids is modulated through their ca-
pacity to up-regulate renal antioxidant enzyme. The glomeruli
isolated from rats given a daily injection of methylpredniso-
lone were found to have signi¢cantly higher activities of anti-
oxidant enzymes than those from untreated rats [38]. This
result is consistent with our data that prednisolone promotes
the EC-SOD production in MCs. Yoshioka et al. reported
that manganese-SOD, which is one of the intracellularly lo-
cated isozymes of SOD, was induced by glucocorticoid in
glomerular cells [39]. Mn-SOD and catalase activities, but
not Cu, Zn-SOD or glutathione peroxidase activities, were
found to increase signi¢cantly in response to methylpredniso-
lone. We assume that the enhancement of EC-SOD produc-
tion is an important e¡ect of prednisolone as well as the
regulation of cytokines in MCs in glomerular disease.
3.5. The e¡ect of prednisolone on EC-SOD production under
the presence of adenylate cyclase inhibitor
Under the stimulated conditions by prednisolone, the EC-
SOD, IL-6 and IL-8 production were associated with cAMP
levels. These results suggest that the production of in£amma-
tory cytokines and EC-SOD production were regulated in
MCs. To clarify the participation of cAMP in production of
EC-SOD, IL-6 and IL-8 production, we studied the e¡ect of
the adenylate cyclase inhibitor in MCs. Fig. 3 shows that in
the presence of adenylate cyclase inhibitor, DDA, the e¡ect of
prednisolone was studied in EC-SOD, IL-6 and IL-8 produc-
tion. In the presence of adenylate cyclase inhibitor, predniso-
lone stimulation showed no e¡ects on EC-SOD, IL-6 or IL-8
production. These results indicate that EC-SOD production is
closely related to the in£ammation regulatory system through
the cAMP system.
Little is known about the regulatory factors of EC-SOD
production in vivo or in vitro. Cyclic nucleotides as the sec-
ond messengers are one of the regulatory factors of cytokine
production in glomerular injury [36], which is also the major
EC-SOD regulatory factor [7]. EC-SOD production in ¢bro-
blasts is induced by treatment of interferon-gamma, cAMP
and ATP [7], but is not induced by oxygen radicals, tumor
necrosis factor, IL-1, IL-6 or IL-8 [40]. The nucleotide se-
quence of the human EC-SOD gene has many transcription
and regulation elements including a cAMP response element
and a glucocorticoid response element, as reported by Foltz et
al. [35]. In renal tissue, cAMP is involved in the various reg-
ulatory systems and its action is regulated by the balance
between adenylate cyclases and cyclic 3P,5P nucleotide phos-
phodiesterases. Thus, it is di⁄cult to clarify the precise action
of cAMP in the regulation of EC-SOD production with or
without the presence of prednisolone. It is conceivable that
the e¡ect of prednisolone on EC-SOD production is via a
cAMP-dependent pathway. We assume that the enhancement
of EC-SOD production is an important e¡ect of prednisolone
as well as the regulation of cytokines in MCs in glomerular
diseases.
4. Conclusion
It was concluded that kidney glomerular MCs produce EC-
SOD like other mesenchymally derived cells. The production
of EC-SOD could be via a cAMP-dependent system and was
regulated in negative correlation with IL-6 and IL-8 when
stimulated by prednisolone or suppressed by PMA. We con-
cluded that the enhancement of EC-SOD production is one of
the important functions of prednisolone.
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